Dr. Saltzstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
18915 Meisner Dr
San Antonio, TX 78258Phone+1 210-499-5158Fax+1 210-679-3730
Education & Training
- University of Texas Medical Branch HospitalsResidency, Urology, 1986 - 1992
- The University of Texas Health Science Center at San AntonioClass of 1986
Certifications & Licensure
- TX State Medical License 1987 - 2025
- American Board of Urology Urology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer Start of enrollment: 2007 Apr 01
- Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance Start of enrollment: 2014 May 08
- Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Start of enrollment: 2014 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 92 citationsThe effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.Ron S. Israeli, Steven J. Rosenberg, Daniel Saltzstein, James E. Gottesman, Howard R. Goldstein
Clinical Genitourinary Cancer. 2007-03-01 - 46 citationsThe Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients wi...David P. Dearnaley, Daniel Saltzstein, John Sylvester, Lawrence Karsh, Bryan A. Mehlhaff
European Urology. 2020-08-01 - 2 citationsImpact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.Daniel J George, Fred Saad, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone
Clinical Genitourinary Cancer. 2023-06-01
Press Mentions
- Challenges Persist in Deploying ADT in Prostate CancerJanuary 11th, 2017
- Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate CancerNovember 30th, 2016
- Expert Panel Highlights State of the Art and Next Steps in Bladder Cancer ParadigmNovember 4th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: